Abstract:Tumor recurrence, driven by the evolution of drug resistance is a major barrier to therapeutic success in cancer. Resistance is often caused by genetic alterations such as point mutation, which refers to the modification of a single genomic base pair, or gene amplification, which refers to the duplication of a region of DNA that contains a gene. Here we investigate the dependence of tumor recurrence dynamics on these mechanisms of resistance, using stochastic multi-type branching process models. We derive tumor extinction probabilities and deterministic estimates for the tumor recurrence time, defined as the time when an initially drug sensitive tumor surpasses its original size after developing resistance. For models of amplification-driven and mutation-driven resistance, we prove law of large numbers results regarding the convergence of the stochastic recurrence times to their mean. Additionally, we prove sufficient and necessary conditions for a tumor to escape extinction under the gene amplification model, discuss behavior under biologically relevant parameters, and compare the recurrence time and tumor composition in the mutation and amplification models both analytically and using simulations. In comparing these mechanisms, we find that the ratio between recurrence times driven by amplification vs. mutation depends linearly on the number of amplification events required to acquire the same degree of resistance as a mutation event, and we find that the relative frequency of amplification and mutation events plays a key role in determining the mechanism under which recurrence is more rapid. In the amplification-driven resistance model, we also observe that increasing drug concentration leads to a stronger initial reduction in tumor burden, but that the eventual recurrent tumor population is less heterogeneous, more aggressive, and harbors higher levels of drug-resistance.

Resistance in oncolytic viral therapy for solid tumors

The role of immune cells in resistance to oncolytic viral therapy

The role of viral infectivity in oncolytic virotherapy outcomes: A mathematical study

Enhancement of chemotherapy using oncolytic virotherapy: Mathematical and optimal control analysis

A general non-local delay model on oncolytic virus therapy

Murine colon cancer derived cells exhibit heterogeneous resistance profiles against an oncolytic virus

Questing for an optimal, universal viral agent for oncolytic virotherapy

Mathematical modelling of the interaction between cancer cells and an oncolytic virus: insights into the effects of treatment protocols

Oncolytic virotherapy for tumours following a Gompertz growth law

Spatiotemporal spread of oncolytic virus in a heterogeneous cell population

Multiscale model for the effects of adaptive immunity suppression on the viral therapy of cancer

Assessing the impact of immunotherapy on oncolytic virotherapy in the treatment of cancer

Treating cancerous cells with a continuous release of virus particles

Theoretical understanding of evolutionary dosing following tumor dynamics

Agent-based and continuum models for spatial dynamics of infection by oncolytic viruses

On the Treatment of Melanoma: A Mathematical Model of Oncolytic Virotherapy

Oscillations in a Spatial Oncolytic Virus Model

A Comparison of Mutation and Amplification-Driven Resistance Mechanisms and Their Impacts on Tumor Recurrence

Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model

Bistability and chaotic behaviors in a 4D cancer oncolytic virotherapy mathematical model: Pspice and FPGA implementations

Modeling oncolytic virus therapy with distributed delay and non-local diffusion